PMID- 35001603
OWN - NLM
STAT- MEDLINE
DCOM- 20220913
LR  - 20220913
IS  - 2724-5365 (Electronic)
IS  - 2724-5985 (Linking)
VI  - 68
IP  - 3
DP  - 2022 Sep
TI  - Probiotics in the treatment of Helicobacter pylori infection: reality and 
      perspective.
PG  - 277-288
LID - 10.23736/S2724-5985.21.02926-0 [doi]
AB  - Helicobacter pylori (H. pylori) infection is one of the most common in the world 
      today, associated with the development of acute or chronic inflammatory diseases 
      of the gastroduodenal tract. In order to eradicate the pathogen, various 
      antibacterial therapy regimens have been proposed, based on the use of several 
      chemotherapeutic drugs and a proton pump inhibitor (PPI). However, recent studies 
      indicate a decrease in antibiotic effectiveness due to both the growth rate of H. 
      pylori resistance and side effects, often due to the development of dysbiosis. 
      One of the promising areas of investigation is the treatment with probiotic 
      therapy of helicobacteriosis. The use of probiotics, in the context of H. pylori 
      infection, has two main reasons. The first is related to the use of certain 
      probiotics to reduce the frequency of undesirable gastrointestinal consequences 
      during H. pylori eradication therapy. The second is associated with the 
      antagonistic effect of individual probiotics on H. pylori and the potentiation of 
      the eradication effect. The purpose of this review was to summarize the latest 
      data on the use of probiotics to enhance H. pylori eradication and to restore the 
      gastrointestinal microbiota. Many unresolved questions, about the choice of the 
      specific composition of the probiotic cocktail, dosage, duration of therapy, 
      mechanisms of the antimicrobial action of probiotics, as well as possible 
      negative consequences of such therapy, remain.
FAU - Isaeva, Guzel
AU  - Isaeva G
AD  - Kazan Research Institute of Epidemiology and Microbiology, Kazan, Russia - 
      guisaeva@rambler.ru.
AD  - Kazan State Medical University, Kazan, Russia - guisaeva@rambler.ru.
FAU - Isaeva, Regina
AU  - Isaeva R
AD  - I.M. Sechenov First Moscow State Medical University - Sechenov University, 
      Moscow, Russia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220110
PL  - Italy
TA  - Minerva Gastroenterol (Torino)
JT  - Minerva gastroenterology
JID - 101777280
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Anti-Bacterial Agents/pharmacology/therapeutic use
MH  - *Helicobacter Infections/drug therapy/microbiology
MH  - *Helicobacter pylori
MH  - Humans
MH  - *Probiotics/therapeutic use
MH  - Proton Pump Inhibitors/pharmacology/therapeutic use
EDAT- 2022/01/11 06:00
MHDA- 2022/09/14 06:00
CRDT- 2022/01/10 08:22
PHST- 2022/01/11 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
PHST- 2022/01/10 08:22 [entrez]
AID - S2724-5985.21.02926-0 [pii]
AID - 10.23736/S2724-5985.21.02926-0 [doi]
PST - ppublish
SO  - Minerva Gastroenterol (Torino). 2022 Sep;68(3):277-288. doi: 
      10.23736/S2724-5985.21.02926-0. Epub 2022 Jan 10.